AUTHORS
Maryam Mooghali, MD, MSc, Cary P. Gross, MD2, Matthew C. Diamond, MD, PhD3, Amylou C Dueck, PhD4, Mallorie H. Fiero, PhD5, Molly M. Jeffery, PhD6, Brie N. Noble7, Jonas Paludo, MD8, Jessica Ritchie, MPH, PMP9, Joseph S. Ross, MD, MHS10, Kathryn J. Ruddy, MD11, Sarah E. Schellhorn, MD12, Michelle E Tarver, MD, PhD13, Gita Thanarajasingam, MD14, Vishal Bhatnagar, MD15, Scott F. Huntington, MD, MPH16
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 US Food and Drug Administration, Silver Spring, Maryland, United States
4 Mayo Clinic, Phoenix, Arizona, United States
5 US Food and Drug Administration, Silver Spring, Maryland, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Phoenix, Arizona, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Yale School of Medicine, New Haven, Connecticut, United States
10 Yale School of Medicine, New Haven, Connecticut, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Yale School of Medicine, New Haven, Connecticut, United States
13 US Food and Drug Administration, Silver Spring, Maryland, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 US Food and Drug Administration, Silver Spring, Maryland, United States
16 Yale School of Medicine, New Haven, Connecticut, United States
ABSTRACT
BACKGROUND
Physical function and overall side-effect burden are patient-reported outcomes central to evaluating cancer treatment tolerability and are key domains recommended by the US Food and Drug Administration for assessment in cancer trials. In4M (NCT05214144) was a prospective multi-modal study that measured physical function and side effect impact from treatment over time. We examined treatment tolerability using patient-reported symptom bother and patient-reported, clinician-reported, performance-based, and wearable measures of physical function among patients receiving chemotherapy for lymphoma.
METHODS
Patients preparing to initiate chemotherapy for lymphoma were asked to wear a Fitbit and to complete electronic patient-reported outcome (ePRO) assessments over 9 months during and after chemotherapy. ePROs included FACT-GP5 (a single-item measure, “I am bothered by side effects of treatment”, scored from 0 [not at all] to 4 [very much]), the PROMIS Physical Function Short Form 8c, and the EORTC QLQ-F17 Physical Function questionnaire. ePROs were delivered weekly for 8 weeks, then monthly until month 9. Clinician-reported outcomes (ECOG performance status), performance outcomes (6-minute walk test), and wearable sensor data (average daily steps) were also collected. Symptom severity, change, and treatment-related symptom bother were assessed using Patient Global Impression of Severity (PGI-S), Patient Global Impression of Change (PGI-C), and FACT-GP5, respectively. Summary statistics were used to evaluate GP5 data, PROMIS Physical Function, and average daily steps (over the prior week) at each timepoint. FACT-GP5 responses were dichotomized as at least somewhat bothered (somewhat, quite a bit, or very much) vs. less bothered (not at all or a little bit). Associations between FACT-GP5 bother category and physical function measures were assessed using Wilcoxon rank-sum tests and Spearman correlation coefficients.
RESULTS
The sample included 63 patients, of which 61 (97%) were newly diagnosed. Median age was 58 (range 23-83) years, and 34 (54%) were male. R-CHOP or pola-R-CHP was the most common regimen (57%), followed by AVD-based therapy (ABVD, BV-AVD, or nivo-AVD) (25%). Radiation followed chemotherapy in 7 (11%) patients.
FACT-GP5 symptom burden increased after baseline through 12 weeks. At baseline, 78% reported “not at all” bother; by week 12, this decreased to 17%, while 40% reported “a little bit,” 27% “somewhat,” 12% “quite a bit,” and 4% “very much”. At 12 weeks, patients with at least somewhat bother on FACT-GP5 had a lower patient-reported physical function (median PROMIS Physical Function t-score of 39.8) than those with less bother (median PROMIS Physical Function t-score of 47.5; p<0.001). From baseline to 12 weeks, median PROMIS Physical Function t-score decreased by 10.4 points among patients with at least somewhat bother while decreasing by 6.4 points among those with less bother (p=0.14).
At 12 weeks, EORTC QLQ-F17 physical function scores showed a similar pattern with median scores ranging from 73.3 among patients with at least somewhat bother to 86.7 among those with less bother (p<0.001). From baseline to 12 weeks, median decrease ranged from 26.7 points among patients with at least somewhat bother to a decrease of 6.7 points among those with less bother (p<0.001). Conversely, clinician-reported ECOG performance status was largely unchanged throughout the 12 weeks. Six-minute walk distance and average daily steps did not show a consistent pattern across FACT-GP5 bother categories, and change-from-baseline values were also variable.
Overall, at 12 weeks, correlations with FACT-GP5 bother were strongest for patient-reported measures: PGI-C (Spearman ρ = −0.69, p<0.001), EORTC QLQ-F17 physical function (ρ = −0.60, p<0.001), and PROMIS Physical Function (ρ = −0.38, p=0.008). Correlations were minimal for clinician-reported ECOG (ρ = 0.04, p=0.81) and average daily steps (ρ = 0.01, p=0.98).
CONCLUSION
This multi-modal study of physical function during lymphoma chemotherapy found that physical function deteriorated more from baseline to 12 weeks in those reporting greater side effect burden. While clinician-reported ECOG performance status, 6-minute walk test results, and daily step counts were not clearly associated with side effect bother, multiple patient-reported physical function measures were associated with side effect bother, which may represent a single-item metric of treatment tolerability.
DISCLOSURES
Maryam Mooghali, MD, MSc: No relevant conflicts of interest to declare.